
JPMorgan lowered the firm’s price target on Omada Health (OMDA) to $25 from $30 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| OMDA | Omada Health, Inc. | 12.51 | -5.64 | -31.08% |
| Name | Price | % Change | |
|---|---|---|---|
| $12.51 | -31.08% |

JPMorgan lowered the firm’s price target on Omada Health (OMDA) to $25 from $30 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Omada Health, Inc. (OMDA) has disclosed a new risk, in the Sales & Marketing category. Omada Health, Inc. faces revenue volatility because its fees depend on monthly enrollment levels from

Omada Health, Inc. (($OMDA)) has held its Q3 earnings call. Read on for the main highlights of the call. Omada Health delivered a strongly positive third quarter, reporting record revenue,

Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on Omada Health, Inc. today and set a price target of $30.00. Craig Hettenbach’s rating is based on a combination of

Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omada Health (OMDA) to $19 from $22 and keeps an Equal Weight rating on the shares. The firm notes

BTIG analyst David Larsen has reiterated their bullish stance on OMDA stock, giving a Buy rating today. David Larsen’s rating is based on Omada Health’s strong third-quarter execution and improved

Canaccord says Omada Health’s (OMDA) Q3 results were “strong,” topping the firm’s and consensus estimates by “a wide margin across the board,” and notes that FY26 revenue guidance was raised

Barclays lowered the firm’s price target on Omada Health (OMDA) to $22 from $24 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

Reports Q3 revenue $91.31M, consensus $85.64M. Total members reached 1.1M, increasing 36% vs. last year, driven by strong enrollment momentum across diabetes and hypertension programs. “Omada Health (OMDA) delivered its

Consensus for FY26 revenue is $338.7M. The company raised its full year guidance following strong growth in diabetes and hypertension programs and record member tenure. Published first on TheFly –
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 16, 2026 | ||||
| buy | Assigned | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Sep 14, 2026 | ||||
| buy | Reiterated | Sep 11, 2026 | ||||
| buy | Reiterated | Sep 11, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $817.04M | $0.12 | $87.74M | 0.97 | 55.36 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.